PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30065099-3	2018	Because the PI3K/AKT/mTOR pathway is one of the major downstream pathways of EGFR, we hypothesized that ibrutinib"s activity might be enhanced by combination therapy with auranofin in NSCLC cells.	ibrutinib	104-113	AKT serine/threonine kinase 1	Homo sapiens	17-20	
30065099-7	2018	The combination of ibrutinib and auranofin led to a dramatically enhanced inhibition of the expression or phosphorylation of multiple key nodes in the AKT/mTOR and MEK/ERK pathways in both cell lines.	ibrutinib	19-28	AKT serine/threonine kinase 1	Homo sapiens	151-154